Sarah C. Fisher

Sarah C. Fisher

Auto-generated profile, based on publicly available information

Sarah C. Fisher

Birth Defects Registry, New York State Department of Health Albany New York USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2013 in Preventive Medicine
Verified
Journal Article
Closed access
SFS.C. Fisher
S.C. Fisher
SKS.Y. Kim
S.Y. Kim
ASA.J. Sharma
A.J. Sharma
RRR. Rochat
R. Rochat
BMB. Morrow
B. Morrow

5 February 2019 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
WZWangjian Zhang
Wangjian Zhang
TSTanya L. Spero
Tanya L. Spero
CNChristopher G. Nolte
Christopher G. Nolte
VGValerie C. Garcia
Valerie C. Garcia
ZLZiqiang Lin
Ziqiang Lin
LBLorenzo Botto
Lorenzo Botto
Background: More intense and longer‐lasting heat events are expected in the United States as a consequence of climate change. This study aimed to project the potential changes in maternal heat exposure during early pregnancy (3–8 weeks post conception) and the associated burden of congenital heart defects ( CHD s) in the future. Methods and Results: This study expanded on a prior nationwide case‐control study that evaluated the association between CHD s and maternal heat exposure during early pregnancy in summer and spring. We defined multiple indicators of heat exposure, and applied published odds ratios obtained for the matching season of the baseline (1995–2005) into the projection period (2025–2035) to estimate potential changes in CHD burden throughout the United States. Increases in maternal heat exposure were projected across the United States and to be larger in the summer. The Midwest will potentially have the highest increase in summer maternal exposure to excessively hot days (3.42; 95% CI, 2.99–3.88 per pregnancy), heat event frequency (0.52; 95% CI, 0.44–0.60) and heat event duration (1.73; 95% CI, 1.49–1.97). We also found large increases in specific CHD subtypes during spring, including a 34.0% (95% CI, 4.9%–70.8%) increase in conotruncal CHD in the South and a 38.6% (95% CI , 9.9%–75.1%) increase in atrial septal defect in the Northeast. Conclusions: Projected increases in maternal heat exposure could result in an increased CHD burden in certain seasons and regions of the United States.

1 May 2017 in Hypertension
Verified
Journal Article
Closed access
PDF file
SFSarah C. Fisher
Sarah C. Fisher
AZAlissa R. Van Zutphen
Alissa R. Van Zutphen
MWMartha M Werler
Martha M Werler
ALAngela E. Lin
Angela E. Lin
PRPaul A. Romitti
Paul A. Romitti
MBMarilyn L. Browne
Marilyn L. Browne
Previous NBDPS (National Birth Defects Prevention Study) findings from 1997 to 2003 suggested that maternal antihypertensive use was associated with congenital heart defects (CHDs). We re-examined associations between specific antihypertensive medication classes and specific CHDs with additional NBDPS data from 2004 to 2011. After excluding mothers missing hypertension information or who reported pregestational diabetes mellitus, a multiple birth, or antihypertensive use but no hypertension, we compared self-reported maternal exposure data on 10 625 CHD cases and 11 137 nonmalformed controls. We calculated adjusted odds ratios [95% confidence intervals] to estimate the risk of specific CHDs associated with antihypertensive use during the month before conception through the third month of pregnancy, controlling for maternal age, race/ethnicity, body mass index, first trimester cigarette smoking, and NBDPS site. Overall, 164 (1.5%) case mothers and 102 (0.9%) control mothers reported early pregnancy antihypertensive use for their hypertension. We observed increased risk of 4 CHD phenotypes, regardless of antihypertensive medication class reported: coarctation of the aorta (2.50 [1.52–4.11]), pulmonary valve stenosis (2.19 [1.44–3.34]), perimembranous ventricular septal defect (1.90 [1.09–3.31]), and secundum atrial septal defect (1.94 [1.36–2.79]). The associations for these phenotypes were statistically significant for mothers who reported β-blocker use or renin–angiotensin system blocker use; estimates for other antihypertensive medication classes were generally based on fewer exposed cases and were less stable but remained elevated. Our results support and expand on earlier NBDPS findings that antihypertensive medication use may be associated with increased risk of specific CHDs, although we cannot completely rule out confounding by underlying disease characteristics.

21 December 2020 in Birth Defects Research
Verified
Journal Article
Closed access
PDF file
DHDominique Heinke
Dominique Heinke
JIJennifer L. Isenburg
Jennifer L. Isenburg
ESErin B. Stallings
Erin B. Stallings
TSTyiesha D. Short
Tyiesha D. Short
MLMimi Le
Mimi Le
FNFor The National Birth Defects Prevention Network
For The National Birth Defects Prevention Network

6 November 2018 in Birth Defects Research
Verified
Journal Article
Closed access
PDF file
MHMeredith M. Howley
Meredith M. Howley
MFMarcia L. Feldkamp
Marcia L. Feldkamp
EPEleni A. Papadopoulos
Eleni A. Papadopoulos
SFSarah C. Fisher
Sarah C. Fisher
KAKathryn E. Arnold
Kathryn E. Arnold
FSfor the National Birth Defects Prevention Study
for the National Birth Defects Prevention Study

1 July 2019 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
MRMarisa A. Ryan
Marisa A. Ryan
AOAndrew F. Olshan
Andrew F. Olshan
MCMark A. Canfield
Mark A. Canfield
AHAdrienne T. Hoyt
Adrienne T. Hoyt
ASAngela E. Scheuerle
Angela E. Scheuerle
TDTania A. Desrosiers
Tania A. Desrosiers